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A major goal of current research in schizophrenia is to understand the biology underlying onset
and early progression and to develop interventions that modify these processes. Biomarkers can
play a critical role in identifying disease state, factors contributing to underlying progression,
as well as predicting and monitoring response to treatment. Once biomarker-based therapeu-
tics are established, biomarkers can guide treatment selection. It is increasingly clear that a
wide range of potential biomarkers should be examined in schizophrenia, given the large
number of genetic and environmental factors that have been identiﬁed as risk factors. New
models for analysis of biomarkers are needed that represent the central nervous system as a
highly complex, dynamic, and interactive system. Many tools are available with which to study
relevant brain chemistry, but most are indirect measures and represent only a small fraction of
the potential etiologic factors contributing to the molecular, structural and functional
components of schizophrenia. This review represents the work of the International Society
for CNS Clinical Trials and Methodology (ISCTM) Biomarkers Working Group. It discusses
advantages and disadvantages of different categories of biomarkers and provides a summary
of evidence that biomarkers representing inﬂammation, oxidative stress, endocannabinoids,
glucocorticoid, and biogenic amines systems are dysregulated and potentially interactive in
early phase schizophrenia. As has been recently demonstrated in several neurodevelopmentalo.2016.01.009
hed by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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D.C. Goff et al.924and neurodegenerative disorders, a multi-modal, longitudinal strategy involving a diverse array
of biomarkers and new approaches to statistical modeling are needed to improve early
interventions based on the fuller understanding.
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biomarkers
As deﬁned by an NIH working group, a biomarker “is a
characteristic that is objectively measured and evaluated as
an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to an interven-
tion”(BDWG, 2001). Biomarkers can be used to make a
diagnosis, to stage an illness, to predict diagnostic conver-
sion or estimate prognosis, or to predict and monitor clinical
response to treatment (FDA, 2014). Efforts to identify
biomarkers that differentiate individuals with schizophrenia
from healthy controls or other psychiatric disorders are
hampered by the heterogeneity of the phenotype and the
diverse assortment of genes and environmental factors that
have been associated with the illness. It may be more
productive to identify subgroups of individuals who share
biological patterns in common that may predict preferential
response to targeted treatments rather than attempt to ﬁnd
a “schizophrenia biomarker”. In order to guide treatment,
biomarkers should reﬂect disease mechanisms that are
relevant to the selection of therapeutic options. Some
schizophrenia risk genes and environmental factors are
involved early in brain development and may produce
alterations in cellular differentiation and connectivity. If
measured early enough, biomarkers for these factors might
identify individuals at risk in order to modify or halt
progression of the aberrant neurodevelopmental process.
For example, in mouse models of maternal immune activa-
tion, interventions directed at maternal inﬂammatory cyto-
kines protect against neurodevelopmental abnormalities in
their offspring (Ito et al., 2010; Pang et al., 2005). Other
risk genes and environmental factors are primarily involved
in the biochemistry of signaling pathways; treatments for
these individuals may target nodes or hubs in these path-
ways which can restore a more functional equilibrium.
Examples include treatments that reduce inﬂammation or
stress if these factors are found to exacerbate symptoms, or
treatments that correct molecular deﬁcits produced by
genetic variants, such as folate supplementation in indivi-
duals with the MTHFR risk allele (Roffman et al., 2013) or
drugs that decrease COMT activity (e.g., tolcapone) in
Val158Val COMT polymorphism subjects (Apud et al.,
2007). The symptoms of schizophrenia reﬂect a convergence
of diverse etiologic factors upon common pathways or
networks which can also be identiﬁed by biomarkers and
can be targeted pharmacologically, as in the case of
dopamine D2 receptor antagonism, which improves psycho-
tic symptoms in most individuals regardless of etiology.
However, to substantially improve current outcomes it will
be necessary to develop a personalized medicine approach
that identiﬁes an individual's relevant genetic andenvironmental risk factors and the resulting biochemical,
functional or structural pathology within a neurodevelop-
mental context and thereby target individualized therapies.
The FDA in their recent guidance on Drug Development
Tools (DDT; Qualiﬁcation Process for Drug Development
Tools; (FDA, 2014)) identiﬁes two separate processes neces-
sary to develop novel biomarkers for drug development. The
ﬁrst step is analytical validation in which the characteristics
and performance of assays are quantitatively described,
including accuracy, precision, reproducibility, linearity, spe-
ciﬁcity and sensitivity. The second step deﬁnes how the
biomarker should be used in the context of clinical manage-
ment or drug development and includes the biomarker's
purpose, its boundaries, the conditions of qualiﬁed use, and
its interpretation. The largest hurdle is to amass enough
clinical data to describe the use and its restrictions (i.e.,
qualiﬁcation) in the patient setting. In the clinical research
literature, statistically signiﬁcant differences in mean
values of analytes or imaging ﬁndings between target
populations and controls groups are often interpreted as
potential biomarkers. However, the predictive value of a
biomarker depends on many factors, including generaliz-
ability across clinical populations, the reliability of the
biomarker based on elements of sample collection, sample
preparation and assay method, the sensitivity and speciﬁ-
city of the biomarker for the speciﬁc target population and
on the relative prevalence of the target population. Due to
issues of poor reliability and generalizability, many promis-
ing biomarkers have failed replication and for those bio-
markers that have successfully achieved replication,
overlap in values between groups may be great enough to
make the biomarker of little or no clinical value. Very few
publications provide the positive predictive value (PPV), i.e.
the ratio of the number of true or accurate positive
predictions / total number of positive test predictions (both
true and false).
When evaluating peripheral biomarkers, it can be difﬁcult
to determine whether they reﬂect active pathologic factors
that may serve as targets for intervention. For example,
biomarkers reﬂecting environmental factors that elevate risk
in the perinatal period, such as inﬂammatory cytokines or
folate deﬁciency, may continue to correlate with disease
characteristics in adulthood (Meyer, 2013; Roffman et al.,
2011). It is not clear whether these biomarkers identify factors
that in adulthood are actively contributing to the illness and
can be targeted by therapeutic approaches or are factors that
disrupted early brain development and are no longer promising
targets for treatment. Even if such biomarkers are no longer
drug targets they may be useful in enriching a clinical trial
sample by removing unwanted variability. In addition, biomar-
kers may reﬂect secondary effects of the illness or treatment
rather than etiologic factors. For example, cigarette smoking,
metabolic syndrome, insomnia and the stress of psychosis can
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the illness, may not play an etiological role in symptom
expression (Fawzi et al., 2011; O'Connor et al., 2009).
In the past, models for schizophrenia focused on single
molecules, such as dopamine or glutamate; the speciﬁcity
of these models largely restricted the breadth of biomarker
candidates. In contrast, recent estimates point to as many
as 6000 to 12,000 single nucleotide polymorphisms (SNPs)
that may contribute to risk for schizophrenia (Andreassen
et al., 2014; Ripke et al., 2013). The focus has accordingly
shifted from individual molecules to pathways as a means of
organizing the vast amount of risk data. Relevant biochem-
ical pathways can best be understood as participants in
highly interactive networks or “webs” that tend to maintain
equilibrium in the face of environmental stress while
maintaining plasticity to respond to environmental chal-
lenge (Fienberg et al., 1998). Due to the high degree of
interactivity, individual components within a network may
inﬂuence many other factors and, in turn be regulated by
multiple factors. A single biomarker may be abnormal
because of multiple modulatory inputs and hence may not
represent a primary etiologic factor nor a treatment target
as it may merely reﬂect rather than inﬂuence a more
fundamental dysregulation of a larger network. On the
other hand, single genes such as microRNAs can affect the
functioning of hundreds of target genes (Delalle et al.,
2014; Potkin et al., 2010; van Erp et al., 2014). More
complex models are required to represent these highly
interactive patterns and to identify sources of disequili-
brium that may be contributing to the illness. New multi-
variate approaches have been developed to identify causal
biomarkers from high-throughput genetic data and may be
applied to this problem (Alekseyenko et al., 2011). Studies
employing genomics, transcriptomics, proteomics, lipido-
mics and methylomics (Aberg et al., 2014; English et al.,
2011; Prabakaran et al., 2004) identify large numbers of
potential biochemical risk factors in a black box approach
unconstrained by existing models. It is also possible to
sample representative pathway biomarkers to assess key
factors, such as inﬂammation, oxidative stress, hypercorti-
solemia, growth factors and methylation that can be used to
identify disease-related dysregulation of fundamental pro-
cesses that inﬂuence a broad range of relevant biochemical
interactions. In addition, points of convergence that are
more proximal to symptom generation can be studied as a
link between key networks and symptoms. One example is
the AKT/mTor pathway that links multiple environmental
inputs, such as stress and inﬂammation, to neuronal plasti-
city and cell survival and may mediate some effects of
antipsychotic medication (Bowling et al., 2014).
The identiﬁcation of illness-related biomarkers can be
confounded by medication treatment, social factors, and
other modifying genes. Studying subjects at genetic or
clinical high-risk for developing schizophrenia (e.g., non-ill
relatives or at-risk adolescents) can avoid the confounds of
medication and disease status. Non-ill high-risk subjects
may have the genetic vulnerability, but the vulnerability has
been insufﬁcient to produce the disease, possibly because
of the lack of additional genetic or environmental inﬂuences
or the presence of compensatory mechanisms. Studies of
adolescents at high-risk based on prodromal symptoms or
familial risk have the advantage of longitudinal follow-up sothat disease- and risk- related events can be separated.
However, such studies require many years to complete and
considerable resources. One approach to addressing these
limitations is to study individuals with schizotypal person-
ality disorder, a disorder within the schizophrenia spectrum.
Converging data support a continuum from severe chronic
schizophrenia to the attenuated schizophrenia-like traits of
schizotypal personality disorder, sharing genetic, brain and
psychophysiologic biomarkers (Siever and Davis, 2004).
Individuals with schizotypal personality disorder may be an
ideal population for biomarker discovery and testing of
novel treatments targeted at those biomarkers (Rosell
et al., 2015).
DNA, blood, CSF and imaging-based biomarkers all pro-
vide information which may differ in relevance according to
the particular question that is addressed. Increasingly,
combinations of peripheral, genetic and imaging biomarkers
are successfully testing hypotheses about relationships
between biological mechanisms, structural and functional
brain imaging changes, and neurodevelopment which may
lead to therapeutic interventions (Mondelli et al., 2011;
Pagliaccio et al., 2014; Roffman et al., 2013). This is in
contrast to studies in oncology that have tended to ﬁnd that
a focus on the single biomarker most proximal to the illness,
e.g., gene expression, may be more predictive than a multi-
modal analysis (Ray et al., 2014). One promising example of
a multimodal approach is the North American Prodrome
Longitudinal Study (NAPLS) Consortium, which is examining
multimodal imaging and peripheral biomarkers to under-
stand factors contributing to progression from prodrome to
schizophrenia (Cannon et al., 2014). Another successful
example of an integrated approach to biomarkers is the
Alzheimer's Disease Neuroimaging Initiative (ADNI) which
has combined clinical measures, imaging, genetics, and CSF
and blood omics biomarkers in the longitudinal analysis of
individuals at risk for developing Alzheimer's Disease
(Weiner et al., 2013). In this paper we will provide an
overview of current biomarkers for clinical characterization
and monitoring of drug treatment in early stage schizo-
phrenia and make recommendations based on existing
models. While these biomarkers may be relevant to other
treatment modalities, including cognitive remediation,
neuromodulation and psychosocial interventions, we have
focused on biomarkers for drug development (Figure 1). In
addition, whereas post-mortem brain markers may contri-
bute to identiﬁcation of pathways for drug development,
this review focuses on biomarkers that are potentially
available in clinical practice.2. Categories of biomarkers
2.1. Brain imaging
There are many strategies for using imaging-based biomar-
kers for drug development and for clinical decision making.
Early in the process of drug development, PET ligand
occupancy studies can establish target engagement to verify
bioavailability and guide dose ﬁnding (e.g., deﬁning the
dose range for lurasidone with 18F-fallypride PET) (Potkin
et al., 2014). In a recent example, Umbricht and colleagues
(Martin-Facklam et al., 2013; Umbricht et al., 2014) used
Figure 1 Graphic description of the continuum of biomarker
development. The determination of the type of biomarker
pertains to a speciﬁc category, such as diagnostic, prognostic,
predictive, pharmacodynamics, surrogate endpoint, etc. Deter-
mining the purpose of the biomarker, helps deﬁne the speciﬁc
regulatory pathway, which in turn informs the Regulatory
strategy for a medical device or a drug development tool.
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centrations to establish the range of therapeutic doses for
clinical trials of the GlyT1 inhibitor, bitopertin. In the
absence of a speciﬁc PET ligand, functional MRI and
electrophysiological approaches can be used to identify
alterations in brain function that may serve as more
sensitive assays than behavioral observation for identifying
CNS drug effects. Such measurable brain effects are argu-
ably more proximal to the etiological cause than symptoms
that are inﬂuenced by many factors, including environmen-
tal context. Measurable changes in biomarkers associated
with treatment, if sufﬁciently sensitive and speciﬁc, can
allow smaller sample sizes in clinical trials or can make
possible studies of shorter duration if the biomarker pre-
dicts longer-term outcome. This approach has been used in
other areas of medicine, e.g., hypercholesterolemia and
blood pressure as biomarkers for long-term cardiovascular
consequences such as myocardial infarction. Additionally
biomarkers can be used to enrich samples in clinical trials by
eliminating subjects with symptoms that do not vary, e.g.,
prodromal subjects who, based on biomarkers, are not
predicted to progress to schizophrenia. Structural MRI and
diffusion tensor imaging have been used to monitor changes
in volume and integrity of brain components which may
predict the long-term course for trials of treatments that
employ neuroprotection or facilitate neuroplasticity (Eack
et al., 2009). Similarly, changes in connectivity measured by
resting state fMRI correlations may identify alterations in
plasticity associated with cognitive enhancement (Díaz-
Caneja et al., 2015; Wang et al., 2014). MR spectroscopy
provides estimates of concentrations of molecules relevant
to drug treatment, and has produced promising ﬁndings
related to neuronal integrity (NAA), glutamate signaling
(Glx), GABA, and oxidative stress (glutathione) (Monin
et al., 2014; Salavati et al., 2015). Poor reproducibility of
single voxel MRS has been problematic for biomarker
research; however, by summing the phase-aligned and
frequency-aligned spectra from a larger brain volume or
using stronger magnets, intra-individual coefﬁcients ofvariation can be reduced below 10% for most analytes
(Kirov et al., 2012). Taken together, imaging approaches
provide the most direct brain measures to classify patients
and evaluate drug effects but of these modalities, only PET
and MRS provide information about biochemical pathways
that mediate pharmacologic treatment response. For the
limited number of molecules for which PET ligands are
available, PET remains the gold standard biomarker.
Structural neuroimaging is the most studied brain endo-
phenotype in psychiatry and offers the opportunity to
understand the anatomy of schizophrenia, but does not
provide sufﬁcient information regarding the mechanisms of
the observed pathology. Functional brain imaging (fMRI,
MRS, and FDG PET) represents a more direct measure of the
functional consequences of genetic risk, although abnorm-
alities of brain structure and function are often related. As
genetic risk genes do not operate in isolation, genetic
pathways and/or abnormal circuitry may be closer to the
underlying causal mechanisms than the abnormal structure
or function of any single anatomical brain area. Circuitry
dysfunction may infer greater risk than the individual
components of the circuitry. Similarly, pathways may infer
greater risk than the individual genes that comprise the
pathway. Resting state activity is measured in a non-task
condition, e.g., at rest, and can be used to identify
networks of co-activated brain areas. A recent analysis
demonstrated a signiﬁcant association between copy num-
ber deletion burden, a known risk factor for schizophrenia,
and disordered resting state functional connectivity, poor
cognitive performance, and changes in regional brain
volume (Martin et al., 2014). Brain imaging can also clarify
the brain effects of candidate risk genes. For example,
Walton and colleagues (Walton et al., 2013) found that
neurogranin SNPs that have been linked to schizophrenia
predicted cortical thickness and abnormal patterns of
activation during a working memory task, thereby linking
speciﬁc functional and morphometric imaging biomarkers
with neurogranin genetic risk, a possible etiological
mechanism. Initiatives such as the Cognitive Neuroscience
Treatment Research to Improve Cognition in Schizophrenia
(CNTRICS) aim to identify new biomarkers including neuroi-
maging to measure cognitive deﬁcits and their response to
new therapies, including cognitive remediation, social cog-
nitive training and intranasal oxytocin (Millan and Bales,
2013; Perez-Rodriguez et al., 2014).
Brain imaging can be used as a quantitative trait (QT) to
discover unanticipated risk genes for schizophrenia. In a
sample of less than 200 subjects, dorsolateral prefrontal
cortex fMRI activation was measured during a working
memory task and used as a QT to identify unanticipated
risk SNPs for schizophrenia including TNIK, a regulator of
glutamate and AMPA transmission (Potkin et al., 2009). A
similar quantitative imaging genetics strategy identiﬁed
microRNA-137 as an unanticipated risk factor for schizo-
phrenia which was conﬁrmed in large case-control studies
and described as an “etiological” mechanism for schizo-
phrenia (Potkin et al., 2010; Ripke et al., 2011). Gene
regulatory networks can be inferred from expression
proﬁles, regulatory motifs, and micro-RNAs and used to
determine which group of genes or pathways is over-
enriched in relation to a diagnostic disorder or cognitive
dysfunction.
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Although infrequently studied in schizophrenia, cerebrosp-
inal ﬂuid (CSF) has been a highly informative source of
biomarkers in Alzheimer's disease and neuroinﬂammatory
disorders (Aluise et al., 2008; Meeker et al., 2011). Because
CSF readily transverses gap junctions to ﬁll spaces between
brain cells, it contains solutes secreted from brain cells,
exosomes, and cell membrane fragments (Johanson et al.,
2008; Delalle et al., 2014). CSF is produced within the
cerebral ventricles by the choroid plexus which ﬁlters blood
at a rate of approximately 0.4 ml/min, replacing the full
volume of CSF every 6 h. In addition, some blood solutes are
found in low concentrations in CSF as a result of passive
diffusion, facilitated transport and active transport. Func-
tioning like the kidney, the choroid plexus maintains home-
ostasis of the brain's extracellular ﬂuid by providing
micronutrients, vitamins, peptides, nucleosides and growth
factors to brain cells; ageing and illness, including oxidative
stress, may compromise this function (Johanson et al.,
2008). Animal studies suggest that the CSF provides the
portal of entry and pathway for circulation of peripheral
immune cells in response to inﬂammation (Schmitt et al.,
2012). CSF biomarkers thus may be informative by identify-
ing invading immune cells, inﬂammatory cytokines and
pathogens, disease-associated extracellular proteins,
alterations in choroid plexus secretory patterns, and diffu-
sion from blood, particularly if the blood brain barrier has
been breached. Transthyretin, which is synthesized primar-
ily by the choroid plexus, serves as a biomarker for choroid
plexus function, whereas albumin, which is not synthesized
in the CNS, serves as a marker for blood brain barrier
integrity. A large decrease in CSF tranthyretin levels was
found in two samples of ﬁrst episode schizophrenia subjects
compared to healthy and psychiatric controls (Huang et al.,
2006); this evidence for impaired choroid plexus function is
all the more impressive given that schizophrenia subjects
had much higher rates of cigarette smoking– nicotine has
been shown to stimulate tranthyretin secretion in rats (Li
et al., 2000). Studies of the ratio of albumin in CSF and
blood have indicated that as many as 30% of schizophrenia
patients have a signiﬁcant disruption of the blood brain
barrier (BBB) (Muller and Ackenheil, 1995); increased per-
meability of the BBB has been linked to inﬂammatory
markers and negative symptoms in patients (Schwarz
et al., 1998) and to ﬁrst and second generation antipsycho-
tics in rat studies (Ben-Shachar et al., 1994). Schizophrenia
patients have disrupted sleep spindles and slow wave sleep
(Manoach et al., 2014). Sleep is related to clearance of a
beta and other toxic substances (Xie et al., 2013). Neural
cells are highly sensitive to their chemical environments and
waste products must be efﬁciently removed from brain
interstitial space into the blood. This “glymphatic trans-
port” can affect both CSF and blood biomarker measures
(Plog et al., 2015).2.3. Blood markers
The brain is unique among organs in its sequestration from
the circulating blood and so measurements of constituents
of blood may poorly reﬂect relevant brain concentrations.The separation of capillaries from extracellular ﬂuid in brain
is accomplished by tight junctions between endothelial cells
and by the choroid plexus which separates CSF from blood.
The BBB protects the brain from bacterial infection and
from circulating antibodies while also preventing the pas-
sage of neuroactive substances from blood that would
otherwise disrupt brain signaling. Sequestration of relevant
biochemical factors can occur at a cellular level as well; for
example, neither kynurenic acid or quinolinic acid cross the
blood brain barrier—kynurenic acid, which modulates NMDA
receptor activity, is only synthesized in astrocytes, whereas
potentially neurotoxic products of the kynurenic pathway
are only found in microglia where they are used in immune
defense (Schwarcz et al., 2012). Blood contains thousands
of proteins and peptides which vary in concentration by a
factor of 1015. Albumin and IgG comprise 80% of proteins in
blood; the roughly 20 proteins that are found in the highest
concentrations must be removed to allow assay of lower
concentration proteins that would otherwise be masked
(Aluise et al., 2008). Preparation of blood samples, which
varies according to the biomarker of interest, is also critical
to ensure valid assays and reliability between studies
(Luque-Garcia and Neubert, 2007). Inconsistencies in the
clinical conditions under which samples are obtained, in
their preparation, and in analytic methods have contributed
to the frequent failures to replicate blood biomarkers; an
effort is underway to standardize these factors (Poste et al.,
2014). Plasma and serum have relative advantages and
disadvantages; plasma requires an anticoagulant that may
affect some analytes (Hosnijeh et al., 2010); in contrast,
during preparation of serum samples, coagulation may
release substances, such as BDNF and inﬂammatory cyto-
kines, from platelets and other cells, thus altering the
proteome. However, in general, sensitivity of serum is
higher than plasma whereas reproducibility of plasma is
greater (Yu et al., 2011). Best studied is BDNF, for which
plasma and whole blood concentrations have been found to
correlate reasonably well with brain levels (r=0.6–0.7) in
rats and pigs (Klein et al., 2011) and with CSF in humans
(r=0.5) (Pillai et al., 2010). The composition of blood may
be highly inﬂuenced by diet, medications, activity and
diseases of peripheral organs, glymphatic and blood brain
barrier integrity can be compromised by inﬂammation and
other disease processes, further complicating blood-based
biomarkers. All of these factors make establishing reliability
and validity of blood biomarkers a challenge.3. Treatment-related genetic markers
Functional polymorphisms of target receptors and drug
metabolizing enzymes can greatly inﬂuence pharmacoki-
netic and pharmacodynamic relationships for a given drug.
Functional polymorphisms of drug metabolizing enzymes
including CYP2D6, CYP2C9, CYP2C19 can result in large
variations in the systemic exposure of the drug with a given
dose. For example, poor CYP2D6 metabolizers can develop
toxic levels of antipsychotic drugs (e.g., aripiprazole,
iloperidone, thioridazine, brexpiprazole), while ultra-rapid
metabolic status is associated with sub-therapeutic levels at
recommended doses (Drozda et al., 2014). Genetic biomar-
kers may also predict adverse drug events. Dopamine
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development of tardive dyskinesia (TD) following antipsy-
chotic treatment (Shamy et al., 2011). Genetic variants
have also been associated with antipsychotic-induced
weight gain (e.g., HTR2C (Kao and Muller, 2013); the
strongest association appears to be between the melano-
cortin 4 receptor (MC4R) gene (rs489693) and second-
generation antipsychotic-induced extreme weight gain
(Malhotra et al., 2012). A strong association between
genetic variation in HLA-DQB1 (6672 G4C) and risk for
clozapine-induced agranulocytosis has also been identiﬁed
(Athanasiou et al., 2011). Examples of genetic biomarkers
predicting therapeutic response to antipsychotics include
genetic variation in the serotonin 2 A receptor (HTR2A) and
the dopamine 2 receptor (DRD2) (Zhang and Malhotra,
2011). In addition, combinations of risk genes may enhance
prediction, as in the example of six risk genotypes (SNPs in
NPAS3, XKR4, TNR, GRIA4, GFRA2, and NUDT9P1) that when
combined into four approximately equal-sized groups highly
predicted response to iloperidone but not ziprasidone in a
discovery sample (Volpi et al., 2009). Such approaches may
have important clinical relevance for drug development in
early psychosis by decreasing subject heterogeneity and
could lead to a precision medicine approach in which
treatment is targeted to subgroups of patients based on
genetic predictors of response and side effects.
Gene expression in peripheral lymphocytes has been
utilized as a marker for gene expression in brain, although
the relationship between the two is not well-established. It
has been estimated that roughly 50% of schizophrenia
candidate genes are expressed in both blood and brain
and that the median correlation for gene expression
between blood and brain is 0.5 (Sullivan et al., 2006).
Comparison of blood and brain gene expression from
separate groups of patients and controls found that 6 of
123 putative peripheral gene expression biomarkers were
also differentially expressed in brains of individuals with
schizophrenia (Glatt et al., 2005). Even within the brain,
different cell types differ markedly in gene expression, as
was recently demonstrated by the comparison of pyramidal
neurons and parvalbumin-positive interneurons in superior
temporal cortex in schizophrenia versus healthy controls
(Pietersen et al., 2014a, 2014b). In addition, abnormalities
in gene expression differ markedly by brain region, as
demonstrated by oligodendrocyte-related genes
(Haroutunian et al., 2007). Studies of peripheral blood
mononuclear cell (PBMC) gene expression in medication-
naïve schizophrenia patients have implicated pathways
involving AKT1 related to inﬂammation and neurodevelop-
ment, many of which normalized with antipsychotic treat-
ment, although the direction of abnormal baseline
expression and change has not been consistent between
studies (Kumarasinghe et al., 2013; van Beveren et al.,
2012). Gene expression in PBMCs may be informative to the
extent that they reﬂect the interactive inﬂuence of the full
genome and these cells share many receptors in common
with CNS cells, particularly with microglia. Additionally,
gene expression may not be a fully reliable indicator of
protein expression or protein activity. For many molecules
that are relevant to brain development and function,
intermediate factors, such as AMPK and mTOR, regulate
the translation from gene expression to protein synthesisbased on the cell's energy status (Mihaylova and Shaw,
2011). For kinases like AKT, phosphorylation status is more
relevant than protein concentration (Franke, 2008). Despite
these many theoretical limitations, PBMC expression of
inﬂammatory and growth factor genes predicted hippocam-
pal volume in early schizophrenia (Mondelli et al., 2011).
Another approach to clarifying the relationship between
genotype and gene expression is the analysis of DNA
methylation which provides information about early envir-
onmental or inherited factors that inﬂuence gene expres-
sion. Analysis of the DNA methylome from whole blood in
schizophrenia participants revealed altered methylation of
multiple genes, including genes involved in hypoxia, infec-
tion and microRNA regulated networks linked to neuronal
differentiation and dopamine receptor expression (Aberg
et al., 2014). In peripheral lymphocytes, gene expression of
enzymes involved in methylation and demethylation are
also altered in schizophrenia samples versus controls (Auta
et al., 2013). In addition, microRNA, which also modulates
gene expression, may also be dysregulated in schizophrenia
(Potkin et al., 2010; Zhang et al., 2014) although ﬁndings in
PBMCs have not been consistent between studies (Delalle
et al., 2014).
4. Factors implicated in early schizophrenia
by biomarkers
4.1. Inﬂammation
It has been estimated that 40% of genes linked to schizo-
phrenia are involved in the brain's response to infection
(Carter, 2009). For example, one of the strongest linkages is
with the major histocompatibility complex which mediates
several aspects of immune response (2014). Among the best
established environmental risk factors for schizophrenia are
exposure in utero to maternal infection, traumatic stress
and pre-eclampsia—all conditions known to release inﬂam-
matory cytokines (Gilmore and Jarskog, 1997). Mice
exposed to maternal immune activation (MIA) exhibit many
structural and functional deﬁcits associated with schizo-
phrenia along with increased expression of genes associated
with hypoxia and cell death and decreased expression of
genes associated with neurodevelopment—particularly with
the migration of GABAergic interneurons (Oskvig et al.,
2012). Studies in mice have identiﬁed alterations in neuro-
nal migration and synaptic function in MIA exposed off-
spring, in addition to microglial priming and dysregulation of
immune function (Knuesel et al., 2014). Alterations in pro-
inﬂammatory and anti-inﬂammatory cytokine levels in off-
spring differ between brain regions and by developmental
stage and did not correlate with blood cytokine levels
(Garay et al., 2013). When applied to schizophrenia this
model suggests that early neurodevelopmental exposure to
inﬂammation may alter the regulation of CNS neuroinﬂam-
matory components but these changes may not be detected
reliably by assay of standard peripheral biomarkers. The
identiﬁcation of a biomarker signature that would identify
individuals with an early developmental history of MIA
potentially could guide the clinical application of preven-
tive interventions derived from this animal model (Zhu
et al., 2014).
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between onset of illness and inﬂammation (Meyer, 2013). As
a result of early exposure to inﬂammation, microglia may be
“primed” and release excessive levels of inﬂammatory
cytokines in response to infection or stress in young adult-
hood. The excessive neuroinﬂammatory response may dis-
rupt glutamatergic signaling, diminish parvalbumin (PV)
expression in interneurons, reduce neuroplasticity and
promote neuronal injury or death. Priming of microglia
may result from interferon gamma (IFNg) exposure which
shifts cells towards the release of pro-inﬂammatory cyto-
kines (Bsibsi et al., 2014). If the inﬂammatory process is
peripheral, tumor necrosis factor-alpha (TNFα crosses the
blood brain barrier and stimulates release of inﬂammatory
cytokines in brain; in addition, IL-6 increases permeability
of the blood brain barrier (Brett et al., 1995). As a
compensatory response to early inﬂammatory exposure,
anti-inﬂammatory or neuroprotective mechanisms, such as
the shunting of tryptophan metabolism towards kynurenic
acid (KYNA) production, may contribute to pathological
antagonism of NMDA receptor transmission (Schwarcz
et al., 2012). It is also possible that alterations in inﬂam-
matory markers are a consequence, rather than cause, of
illness onset since the psychological stress associated with
psychosis might produce an elevation of inﬂammatory
markers.
The most direct marker for CNS inﬂammation is provided
by PET ligands targeting the mitochondrial translocator
protein (TSPO, aka peripheral benzodiazepine receptor
protein [PBR]), which is expressed by activated microglia.
Binding of the TSPO ligand, [11(C)]PBR28, was shown to
increase by 62% following systemic infection with e. coli in
nonhuman primates; this increase in activated microglia
signiﬁcantly correlated with elevations in serum concentra-
tions of the inﬂammatory cytokines, Il-1b and IL-6
(Hannestad et al., 2012). Studies with ﬁrst and second
generation TSPO ligands in schizophrenia have produced
inconsistent evidence for microglial activation (Doorduin
et al., 2008; Kenk et al., 2014; Takano et al., 2010; van
Berckel et al., 2008); evidence for neuroinﬂammation was
strongest for early stage patients and most prominent in the
hippocampus. The poor selectivity of TSPO binding limited
interpretation of results from the ﬁrst generation of ligands
(e.g., 11C-PK11195) and genetically-determined differences
in TSPO binding afﬁnity complicates interpretation of newer
ligands such as 18F FEPPA (Owen et al., 2012). In addition,
microglial activation may not always signify a neurotoxic
process since microglia are also involved in neurogenesis,
pruning, and can play a neuroprotective role (Chen et al.,
2014; Wake et al., 2013).
Blood and CSF markers in schizophrenia suggest a mixed
picture early in the course of illness of both inﬂammatory and
anti-inﬂammatory markers, which may reﬂect dysregulated
immune activation and compensatory neuroprotective
responses to chronic inﬂammation (Drexhage et al., 2011;
Freudenreich et al., 2010). Inﬂammatory cytokines in blood
are elevated in acute psychosis along with elevated CSF
concentrations of the neuroprotective NMDA antagonist,
kynurenic acid (Linderholm et al., 2012), the anti-
inﬂammatory endogenous cannabinoid, anandamide (Leweke
et al., 2007) and the glial-secreted molecule, S100B which has
concentration-dependent neuroprotective or neurotoxicactivity (Aleksovska et al., 2014; Yelmo-Cruz et al., 2013).
Of the cytokines that are reliably measured in CSF (IL-6, IL-8 &
IL-1B), only IL-1B was elevated in CSF of ﬁrst episode patients
(Soderlund et al., 2009). IL-1B is released by activated
microglia under conditions of inﬂammation and can be
released in response to psychological stress (O'Connor et al.,
2009). IL-1B stimulates inﬂammatory pathways, increases DA
and cortisol levels (Song et al., 2007) and increases kynurenic
acid levels by inducing the TDO (tryptophan 2,3-dioxygenase)
enzyme (Lavebratt et al., 2014). IL-1B also inhibits human
hippocampal neurogenesis (Zunszain et al., 2012). In chronic
patients, PBMC gene expression studies suggest a shift from
Type I inﬂammatory response to a Type 2 anti-inﬂammatory
states (Freudenreich et al., 2010). In a recent meta-analysis,
Miller and colleagues found that inﬂammatory cytokines IL-1B,
IL-6, and TGF-beta are elevated in blood during episodes of
acute illness, whereas elevation of IL-12, IFN-gamma, TNF-
alpha, and sIL-2R may be trait markers (Miller et al., 2011). In
serum samples of medication-naïve ﬁrst episode psychosis
subjects, IL-1B, IL-6, TNFα were found to decrease with
risperidone treatment (Song et al., 2014). In a sample of
subjects from the NAPLS study of individuals at high risk for
conversion from prodrome to schizophrenia, blood levels of
inﬂammatory cytokines predicted gray matter loss and transi-
tion to schizophrenia (Cannon et al., 2014). In summary,
inﬂammatory markers in blood and IL-1B in CSF are elevated
in acute, early psychosis, possibly reﬂecting immune cell
“priming” in utero followed by a “second hit” in young
adulthood which may be an infectious process or psychological
stress. While it may not be clear whether inﬂammation is a
cause or consequence of psychosis, it interacts with multiple
transmitters and molecular networks implicated in schizo-
phrenia and inﬂammatory biomarkers appear to be predictive
of illness course.4.2. Cannabinoids
The endocannabinoid system also links inﬂammation, corti-
sol release and stress to schizophrenia and modulates
glutamate, dopamine and GABA transmission (Pistis et al.,
2002). The cannabinoid CB1 and CB2 receptors are found in
peripheral and CNS stress-responsive circuits and immune
cells and may be viewed as a primary homeostatic mechan-
ism (Bioque et al., 2013). PET studies using the [18F]MK-9470
CB1 ligand found upregulation of CB1 receptors in the
mesocorticolimbic regions in drug-naïve schizophrenia
patients which inversely correlated with negative symptoms
and depression (Ceccarini et al., 2013). It is not clear
whether these alterations in CB1 receptors represent a
pathological mechanism or a compensation in response to
dopamine dysregulation. In contrast, CB2 knockout mice
display behaviors consistent with schizophrenia (Ortega-
Alvaro et al., 2011).
The endogenous cannabinoid receptor agonist, ananda-
mide, reduces inﬂammation by blocking microglial activation
and stimulates neurogenesis. Anandamide concentrations in
CSF were increased 10-fold in medication-naive ﬁrst episode
patients who were not heavy cannabis abusers (lifetime
user5 times) and inversely correlated with psychotic symp-
toms (Leweke et al., 2007). In contrast, medication-naïve ﬁrst
episode schizophrenia subjects who were heavy cannabis users
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anandamide concentrations, even if they had been abstinent
from marijuana for several weeks. Elevated concentrations of
CSF anandamide were also found in individuals who met
criteria for ultra-high risk—among this group, lower CSF levels
of anandamide predicted progression to schizophrenia (Koethe
et al., 2009). While CSF anandamide appears to be a promising
biomarker, serum anandamide concentrations failed to differ-
entiate groups (Leweke et al., 2007). In PBMCs, mRNA for the
endocannabinoid synthesizing enzymes, N-acyl phosphati-
dlyethanolamine phospholipase (NAPE) and diacylglycerol
lipase (DAGL) were decreased and mRNA for the endocanna-
binoid degrading enzymes, fatty acid amide hydrolase (FAAH)
and monacylglycerol lipase (MAGL) were increased (Bioque
et al., 2013). FAAH expression inversely correlated with total
symptom scores (Bioque et al., 2013). Cannabidiol, an endo-
genous low-afﬁnity agonist at cannabinoid receptors, elevates
anandamide levels by blocking degradation by FAAH, and was
shown in one study to have potent antipsychotic effects,
comparable to the antipsychotic, amisulpiride (Leweke et al.,
2012). Cannabidiol reduces release of Th1 pro-inﬂammatory
cytokines and increases release of Th2 anti-inﬂammatory
cytokines. In summary, CSF anandamide is elevated in ﬁrst
episode patients with psychosis, shifts the immune response
from pro-inﬂammatory to anti-inﬂammatory, decreases corti-
sol release, and is associated with reduced symptom expres-
sion. Potential biomarkers include CSF anandamide
concentrations and PBMC expression of NAPE, FAAH and MAGL.4.3. Glutamate
The ketamine model of schizophrenia posits decreased
activation of glutamatergic NMDA receptors on inhibitory
GABAergic interneurons resulting in excessive glutamate
release from pyramidal neurons and disruption of gamma
oscillatory synchrony (Lisman et al., 2008; Olney and Farber,
1995). In mice, NMDA antagonists produce an inﬂammatory
response which increases oxidative stress and decreases PV
(parvalbumin) expression of inhibitory GABAergic interneur-
ons (Behrens and Sejnowski, 2009). Glutamate concentra-
tions are elevated in CSF and blood in medication-free
schizophrenia patients (Beckmann and Gattaz, 2002) and
elevated levels of glutamate measured by MRS have been
associated with hippocampal volume loss (Kraguljac et al.,
2013). Serum glutamate levels increase with antipsychotic
treatment (Beckmann and Gattaz, 2002; Evins et al., 1997;
Goff et al., 2002) and were found to increase following a
switch from haloperidol to olanzapine (Goff et al., 2002).
Olanzapine-associated elevation in cingulate cortex gluta-
mate and glutamine (Glx) levels predicted improvement of
negative symptoms (Goff et al., 2002). In healthy subjects,
CSF and serum glutamate concentrations were signiﬁcantly
correlated (r=0.67) (Alfredsson et al., 1988). Kynurenic
acid (KYNA) a metabolite of tryptophan, and an NMDA
antagonist, has been found to be elevated in CSF of patients
with schizophrenia (Linderholm et al., 2012) and bipolar
patients with psychotic features (Olsson et al., 2010). As an
antagonist at the glycine site of the NMDA receptor, KYNA is
neuroprotective against glutamatergic excitotoxicty but
may contribute to psychosis and cognitive impairment.
Because KYNA does not cross the blood brain barrier, bloodlevels are not informative; however kynurenine is actively
transported into the brain and metabolized by astrocytes to
KYNA (Javitt, 2014). Plasma concentrations of tryptophan
and its metabolites did not differ between ﬁrst episode
patients and healthy controls (Condray et al., 2011). In
summary, dysregulation of glutamate signaling is linked to
inﬂammation and symptoms of schizophrenia; kynurenic
acid in particular may play a role in symptom production
in schizophrenia but because it does not cross the blood
brain barrier, only CSF levels appear to be informative.
4.4. Oxidative stress
Oxidative and nitrosative stress result from an imbalance
between release of reactive oxygen and nitrogen species
and a deﬁciency in endogenous antioxidants. The brain is
particularly vulnerable because of its high utilization of
oxygen and the presence of redox-active metals. Oxidative
stress can damage lipid membranes, proteins and DNA while
also dysregulating redox-sensitive processes such as NMDA
receptor activation, cell differentiation and protein synth-
esis. Oxidative stress also impairs mitochondrial function,
oligodendrogia-mediated myelination and expression of PV
in interneurons. Deﬁcits in antioxidant capacity may result
from genetic vulnerability, or may result from early devel-
opmental exposure to maternal immune activation. In
addition, synthesis of the endogenous antioxidant, reduced
glutathione (GSH), requires the trans-sulfuration pathway
which is dependent on folate. GSH, glutathione disulﬁde
(GSSG) and glutathionylated proteins (PSSG) are sensitive
and reliable markers of oxidative stress but blood samples
require pretreatment to prevent oxidation (Rossi et al.,
2006). Thioredoxin and thioredoxin reductase are anti-
oxidants that are released from neurons, glial and the
choroid plexus in the presence of oxidative stress (Silva-
Adaya et al., 2014) and are involved in cell survival, cell
proliferation and differentiation. Serum thioredoxin levels
were elevated in medication naïve FEP patients compared
to healthy controls and levels signiﬁcantly correlated with
psychosis, whereas levels were not elevated in chronic
patients suggesting an inﬂammatory process associated with
onset of schizophrenia (Zhang et al., 2009). In medication
naïve childhood onset FEP, red blood cell total GSH sig-
niﬁcantly predicted brain volume loss over a two-year
follow-up (Fraguas et al., 2012). In antipsychotic-naïve
FEP patients, baseline blood measures of antioxidant status
and of oxidative stress signiﬁcantly predicted cognitive
functioning after 6 months of treatment (Martinez-
Cengotitabengoa et al., 2012).
4.5. Cortisol
Glucocorticoids are released by the hypothalamus in
response to stress and act on glucocorticoid and mineralo-
corticoid receptors to rapidly modulate neuronal activation
while also modulating gene expression (Groeneweg et al.,
2011). Glucocorticoids act on dopamine pathways to modify
stress-related behavior and cognitive function (McEwen,
2013). Early exposure to stress may produce epigenetic
changes to ventral tegmental dopamine neuron ﬁring rele-
vant to psychosis (Niwa et al., 2013; Pruessner et al., 2004).
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signaling and enhances working memory, whereas chronic
stress or glucocorticoid treatment produces reversible neu-
ronal atrophy in prefrontal cortex and hippocampus and loss
of neurogenesis (Sousa and Almeida, 2012). The prefrontal
cortex in adolescence is particularly sensitive to chronic
stress (Yuen et al., 2012). In humans, low parental care is
associated with increased ventral striatal dopamine release
in response to stress, but not in subjects with high parental
care; salivary cortisol concentrations positively correlated
with striatal dopamine release under stress (Pruessner
et al., 2004). Studies of salivary and blood cortisol levels
in ﬁrst episode psychosis have generally found hypercorti-
solemia which normalizes with antipsychotic treatment and
does not consistently correlate with symptoms (Karanikas
et al., 2014; Mondelli et al., 2010). Salivary cortisol levels
have predicted decreased hippocampal volume in ﬁrst
episode schizophrenia (Mondelli et al., 2011) and PBMC
expression of glucocorticoid receptor genes has also pre-
dicted hippocampal volume and response of depression to
treatment (Cattaneo et al., 2013).
4.6. Methylation
Epigenetic factors inﬂuence DNA methylation of genes
involved in neurodevelopment, including BDNF and the gluco-
corticoid receptor. Two enzymes involved in DNA methylation
and demethylation pathways, DNA-methyltransferase (DNMT1)
and ten-eleven translocator-1 methylcytosine deoxygenase
(TET1), are increased in corticolimbic structures in schizo-
phrenia brain. Lymphocyte gene expression of these enzymes
is similarly elevated in ﬁrst episode and chronic patients, but
failed to correlate with symptoms in chronic patients who
were treated with antipsychotics (Auta et al., 2013). BDNF
gene expression, which is regulated by methylation/demethy-
lation pathways, signiﬁcantly negatively correlated with lym-
phocyte expression of DNMT1 (Auta et al., 2013). A third
trimester dietary deﬁciency of folate, which is the primary
source of methyl groups, is associated with increased risk of
neurodevelopmental deﬁcits, including schizophrenia. Serum
folate concentrations are highly correlated with CSF concen-
trations (r=0.7) across a typical range of concentrations, but
at high serum concentrations achieved with folate supplemen-
tation, CSF concentrations plateau (Obeid et al., 2007). In
patients with schizophrenia, low serum folate concentrations
in combination with genotypes associated with a reduced
capacity to absorb and convert dietary folate to the methyl-
donor (e.g., SAM, S-adenosylmethionine) predict negative
symptoms and their response to folate supplementation
(Roffman et al., 2011, 2013). A deﬁcit of methylation capacity
might also impair antioxidant defenses by decreasing glu-
tathione synthesis, impair NMDA receptor transmission by
elevating homocysteine levels, and disrupt synthesis of neuro-
transmitters and DNA (LaSalle, 2011).
5. Recommendations
For a molecular characterization of illness onset and
progression that could guide pharmacologic interventions,
direct longitudinal measurement of gene expression and
protein concentrations within individual cell types andacross brain regions would be ideal to construct a dynamic,
interactive model. However, in clinical practice we are left
with very indirect measures from blood, imaging, and
possibly CSF. One cannot assume that peripheral blood
biomarkers reﬂect CNS concentrations as the relationship
between peripheral blood and CNS concentrations can be
quite variable. The ultimate predictive value of models
based on these markers remains to be established, although
current ﬁndings with inﬂammatory markers in schizophrenia
have been quite promising. The emerging technology of
induced pluripotent stem cells (IPS), derived from periph-
eral somatic cells of patients with schizophrenia, opens a
promising new avenue to explore disease mechanisms of
schizophrenia. IPS cells provide a viable source of human
central nervous system cell lines – including neurons – for
biomarker discovery and early testing of target engage-
ment, mechanism and response to medications (Brennand
et al., 2011).
Given the large inter-individual variability in biomarker
patterns, in blood brain permeability, and in genetic
variants associated with risk, longitudinal studies examining
within subject change in large samples, employing genotyp-
ing along with CSF, PET and MRS measures, may be most
informative to develop predictive models for drug develop-
ment. Peripheral biomarkers can be identiﬁed which best
correlate with these more direct measures of brain bio-
chemistry. For such efforts to be successful, close attention
must be paid to subject selection, standardization of
conditions under which biomarkers are obtained, methods
of sample preparation, and analytic methods. In addition,
new methods for data analysis must be employed to derive
and compare the multiple permutations of combinations of
variables that represent multiple pathways to illness onset
and progression.
Finally, an important question is the appropriate clinical
role for biomarker and genetic testing in clinical practice.
This is especially relevant since such testing is becoming
increasingly available from commercial vendors. There are
important social, privacy, policy, and ethical issues involved
in the widespread adoption of such testing, including the
need to train clinicians on their meaning and
appropriate use.
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